news
Antibody response varies for Big Pharma COVID vaccines
Pfizer, Moderna and Johnson & Johnson COVID-19 vaccines produced varied neutralising antibody levels when assessed for short- and long-term response, says study.
List view / Grid view
Johnson & Johnson
news
Johnson & Johnson appoints new Executive Vice President, Pharmaceuticals, R&D
An executive from Sanofi has been appointed as Johnson & Johnson’s new Executive Vice President of Pharmaceuticals, R&D.
news
Major M&A deals on 2023 agenda, says report
Subin Baral, EY Global Deals Leader, Life Sciences, recounts the global M&A trends in 2022 and predicts activity for 2023 in EY’s 2023 M&A Firepower report.
news
Top biopharma firms report Q3 market capitalisation decline
The top 20 biopharma companies averaged a market capitalisation decline of $3.45 trillion in Q2 to $3.14 trillion in Q3 2022, says GlobalData.
news
Quantifying proteins en masse using coulometric mass spectrometry
Coulometric mass spectrometry (CMS) fully quantities proteins without using traditional lab sample testing standards, promising faster vaccine and drug advancement.
news
Energize initiative to boost renewable energy access for pharma suppliers
The Energize programme will allow 10 big pharma companies to engage with renewable energy suppliers and address their greenhouse gas emissions.
news
J&J’s Ebola vaccine regimen demonstrates immune response
Johnson & Johnson’s Ebola vaccine regimen, Zabdeno® and Mvabea®, generated robust humoral immune responses in adults and children.
news
HIV vaccine fails to protect women against infection
The investigational vaccine tested in sub-Saharan Africa posed no safety concerns but did not provide sufficient HIV protection.
article
How new risk-sharing strategies can help ensure faster access to COVID-19 vaccines
In this article, Charles River Associates (CRA) delves into why traditional vaccine procurement schemes are not fit for purpose during the pandemic and how both governments and manufacturers must adapt to manage the greater level of risk associated with pandemic vaccine development and distribution.
article
The pandemic and the pharmaceutical world
Pharmacist Ezeokafor Ifeoma Charity explores to what extent COVID-19 has prompted the growth of the pharmaceutical industry.
news
Johnson & Johnson’s COVID-19 vaccine safely elicits an immune response
An interim analysis of Phase I/II trial data shows 90 percent of 18-55 year olds had a neutralising antibody response that lasts at least two months.
news
Japan has pre-ordered COVID-19 vaccine doses for more than four times its population, says report
Japan has procurement deals with half of the companies leading the COVID-19 vaccine development race, according to GlobalData.
news
UK Prime Minister visits the UK Vaccines Manufacturing and Innovation Centre (VMIC)
Prime Minister Boris Johnson visited the construction site of the VMIC and met scientists and engineers at the forefront of the UK’s COVID-19 response.
news
Biopharma pledges to uphold scientific integrity in COVID-19 vaccine development
Nine biopharma CEOs pledged to make the integrity of the scientific process and sufficient supply priorities in the development of COVID-19 vaccines.
article
Developing a preventive vaccine regimen to tackle Ebola
Earlier this year, Johnson & Johnson announced the first major regulatory approval of a vaccine developed by Janssen for the prevention of Ebola. Nikki Withers spoke with the Global Head of Vaccines, Johan Van Hoof, to discover what technologies were used and how they are now being leveraged to develop…
